A Randomized Phase 2a, Double-blind, Placebo-Controlled Study Examining the Safety and Efficacy of BOL-DP-o-08 in Patients With Endometriosis Syndrome.
Latest Information Update: 13 Dec 2022
At a glance
- Drugs BOL DP o 08 (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Sponsors BOL Pharma
- 07 Dec 2022 Planned End Date changed from 15 Apr 2023 to 1 Dec 2020.
- 07 Dec 2022 Planned primary completion date changed from 15 Mar 2023 to 1 Dec 2020.
- 07 Dec 2022 Planned initiation date changed from 1 Dec 2021 to 1 Jan 2019.